Matinas Biopharma Holdings Inc
Company Overview
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics using its lipid nanocrystal (LNC) platform delivery technology. The company's primary focus is on developing treatments for serious infections and other diseases with significant unmet medical needs.
The company's lead product candidate is MAT2203, an oral formulation of amphotericin B developed using the LNC platform technology, which is being developed for the treatment of serious fungal infections. Additionally, they are developing MAT2501, an oral formulation of amikacin for acute bacterial infections.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Matinas Biopharma Holdings Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.